 |
 |
 |
 |
|
 | Novel drug delivery devices for the respiratory drug market | Private | Early / 2007 |
|
 | Novel small molecule therapeutics for ophthalmic diseases | Private | Start-up / 2007 |
|
 | Developing modified form of heparin to ameliorate cardiac ischemia-reperfusion injury following myocardial infarction | Private | Start-up / 2006 |
|
 | Novel antibiotics using patented bacterial RNA targets to treat pathogens resistant to existing drugs | Private | Seed / 2006 |
|
 | Specialty pharmaceuticals for dermatology based on proprietary drug delivery technologies | Private | Early / 2006 |
|
 | Novel anti-inflammatory agents based on endogenous mediators of inflammation resolution | Private | Seed / 2005 |
|
 | Therapeutics that target hypoxic cells to treat cancer and benign prostatic hyperplasia | IPO 2005 | Early / 2003 |
|
 | Small molecule therapeutics for genetic disorders | IPO 2007 | Seed / 2002 |
|
 | Vaccine development | Private | Seed / 2002 |
|
 | Drug delivery technology for localized treatment of disease | IPO 2000 | Later / 1999 |
|
 | Computerized systems for the analysis and prediction of clinical compounds' ADME/Tox properties | Acquired by ArQule, Inc., 2001 | Early / 1999 |
|
 | Cellular and proteomics approaches to target validation for drug development | Private | Seed / 1998 |
|
SELECT HISTORICAL INVESTMENTS |
|
 | Complement inhibition for cardiovascular and inflammatory diseases | IPO 1996 | Early / 1994 |
|
Khepri Pharmaceuticals, Inc. | Development of proteases and their inhibitors as therapeutics | Acquired by Arris Pharmaceuticals, 1995 | Early / 1994 |
|
 | Non-absorbed pharmaceuticals to emilinate target substances from the gastrointestinal tract | IPO 1995; Acquired by Genzyme Corporation, 2000 | Early / 1994 |
|
Luekosite, Inc. | Treatment for inflammatory and autoimmune diseases | IPO 1998; Acquired by Millennium Pharmaceuticals, Inc., 1999 | Early / 1994 |
|
 | Biopharmaceuticals in the fields of cardiovascular disease, oncology, and infectious diseases | IPO 1994; Merged with Megabios, 1999, to create Valentis, Inc. | Early / 1993 |
|
 | Therapeutics for diseases and disorders of the central nervous and immune systems | IPO 1996 | Start-up / 1993 |
|
 | Biotherapeutics for cancer treatment | IPO 1997 | Start-up / 1992 |
|
 | Prevention and treatment of cardiovascular disease | IPO 1996 | Early / 1992 |
|
Chiroscience | Chiral pharmaceutical development | IPO 1994; Merged with Celltech Group, 1999 | Early /1992 |
|
 | Treatment for acute cardiovascular conditions | IPO 1993 | Early/1991 |
|
 | Provider of a leading integrated platform of genomic technologies and services | IPO 1993 | Start-up / 1991 |
|
 | Chronic inflammatory disease therapeutics | IPO 1991 | Start-up / 1990 |
|
 | Autoimmune disease therapeutics | IPO 1994 | Early / 1989 |
|
 | Neurologic disorder therapeutics | IPO 1989 | Start-up / 1988 |
|
 | Wound healing agents | IPO 1989 | Early / 1987 |
|
 | Biopesticides | IPO 1987 | Later / 1986 |
|
 | Discovery and development of small molecules for cancer and immunological diseases | IPO 1987 | Start-up / 1986 |
|
Nova Pharmaceutical Corp. | Drug screening and therapy for brain tumors | IPO 1983; Merged with CalBio, now Scios Inc. | Start-up/1982 |
|
 | Agricultural biotechnology | IPO 1984 | Start-up / 1981 |
|
Genetic Systems Corp. | Diagnostics for sexually transmitted diseases and monoclonal antibody therapeutics | IPO 1981; Acquired by Bristol-Myers Squibb 1985 | Start-up/1981 |
|
